Ibex Preclinical Research

Executive Summary

Ibex Preclinical Research is a Seattle-based contract research organization (CRO) founded in 2018, providing GLP-compliant preclinical testing services for medical device development. The company specializes in large-animal and cadaver models to support in vivo studies, surgical model development, and physician training, with expertise spanning orthopedics, spine, soft tissue surgery, and interventional/minimally invasive devices. By enabling sponsors to generate robust data for regulatory submissions, Ibex plays a critical role in de-risking device development and accelerating time-to-market. As a private, pre-revenue-stage company, its value is tied to the success of its client programs and its ability to secure repeat business and expand its service portfolio. Ibex operates in a growing medical device CRO market driven by increasing regulatory complexity and demand for outsourcing. The company's focus on GLP compliance and large-animal models positions it well for partnerships with medtech firms seeking reliable preclinical data. While competition includes larger CROs, Ibex’s niche expertise offers differentiation. Key catalysts include facility expansions, new service offerings (e.g., advanced imaging), and securing contracts with top-tier device companies. With a lean team and limited financial disclosure, near-term risks center on customer concentration and the need for continuous quality assurance.

Upcoming Catalysts (preview)

• Q4 2026New GLP-compliant facility expansion or accreditation70% success
• Q2 2026Major contract award from a top-10 medical device company50% success
• Q4 2026Launch of advanced interventional model development service65% success